Peter Rhee
Surgical Critical Care Valhalla, NY Medical Doctor
NPI 1033278304 CMS profile 319311
100 Woods Rd, Valhalla, NY 10595
General payments
$4,063
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Peter Rhee of Valhalla, NY is reported in the CMS Open Payments database as having received $4,063 across 14 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 68th percentile of Surgical Critical Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $270 | 2 | |
| 2024 | General | $67 | 2 | |
| 2022 | General | $3,009 | 2 | |
| 2021 | General | $380 | 4 | |
| 2019 | General | $338 | 4 |
Beside peers
- Peter Rhee
- Surgical Critical Care median
- Middle half of Surgical Critical Care
- National median
In program year 2025, general payments to Peter Rhee were reported at $270. Among 1,068 Surgical Critical Care profiles paid that year, the median was $231 and the middle half received between $82 and $1,489.
Show as a table
| Year | Peter Rhee | Surgical Critical Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $338 | $161 | $57–$631 | $163 |
| 2020 | $0 | $116 | $33–$383 | $114 |
| 2021 | $380 | $121 | $37–$475 | $132 |
| 2022 | $3,009 | $163 | $53–$789 | $149 |
| 2023 | $0 | $188 | $67–$1,031 | $160 |
| 2024 | $67 | $216 | $80–$1,133 | $164 |
| 2025 | $270 | $231 | $82–$1,489 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 28 billing codesPaid by Medicare
$15,273
Medicare patients
43
Services billed
123
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Diabetes | 75% | |
| High blood pressure | 75% | |
| Depression | 53% | |
| Arthritis | 49% | |
| Ischemic heart disease | 42% | |
| Chronic kidney disease | 42% | |
| Alzheimer's or dementia | 42% | |
| Heart failure | 37% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
14 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgical Critical Care in New York
Mohammad Gilani
Surgical Critical Care · Brooklyn, NY
Ibrahim Abd El-Shafy
Surgical Critical Care · Mineola, NY
Marcel Tafen Wandji
Surgical Critical Care · Kingston, NY
Matthew Chatoor
Surgical Critical Care · New York, NY
Ilya Shnaydman
Surgical Critical Care · Valhalla, NY
Kartik Prabhakaran
Surgical Critical Care · Valhalla, NY
Related records
Surgical Critical Care in New York
Practitioners in the same specialty and state, ranked by reported value.
All Surgical Critical Care
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.